Cargando…

Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia

BACKGROUND: Triple negative breast cancer (TNBC) has been classified as a disease subgroup defined by the lack of expression of estrogen and progesterone receptors as well as the absence of the human epidermal growth factor receptor-2 (HER2) overexpression. Germline mutations in the BRCA1 gene have...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahfoudh, Wijden, Bettaieb, Inchirah, Ghedira, Randa, Snoussi, Kaouther, Bouzid, Nadia, Klayech, Zahra, Gabbouj, Sallouha, Remadi, Yassmine, Hassen, Elham, Bouaouina, Noureddine, Zakhama, Abdelfateh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458830/
https://www.ncbi.nlm.nih.gov/pubmed/30975216
http://dx.doi.org/10.1186/s12967-019-1873-8
_version_ 1783410093251887104
author Mahfoudh, Wijden
Bettaieb, Inchirah
Ghedira, Randa
Snoussi, Kaouther
Bouzid, Nadia
Klayech, Zahra
Gabbouj, Sallouha
Remadi, Yassmine
Hassen, Elham
Bouaouina, Noureddine
Zakhama, Abdelfateh
author_facet Mahfoudh, Wijden
Bettaieb, Inchirah
Ghedira, Randa
Snoussi, Kaouther
Bouzid, Nadia
Klayech, Zahra
Gabbouj, Sallouha
Remadi, Yassmine
Hassen, Elham
Bouaouina, Noureddine
Zakhama, Abdelfateh
author_sort Mahfoudh, Wijden
collection PubMed
description BACKGROUND: Triple negative breast cancer (TNBC) has been classified as a disease subgroup defined by the lack of expression of estrogen and progesterone receptors as well as the absence of the human epidermal growth factor receptor-2 (HER2) overexpression. Germline mutations in the BRCA1 gene have been associated with TNBC. Approximately 70% of breast cancers arising in BRCA1 mutation carriers and up to 23% of breast cancers in BRCA2 carriers display a triple negative phenotype. However, the contribution and the frequency of BRCA1 mutations in individuals with TNBC, not specifically selected for age at diagnosis or enriched family history of breast/ovarian cancer, have not been investigated in the Tunisian population and are to be established. The aim of the present study was to assess the contribution and the prevalence of recurrent BRCA1 germline mutation (5382inC) in Tunisian women with TNBC unselected for family history or age at onset. METHODS: For BRCA1 5382inC mutation detection, the exon 20 coding region and exon–intron boundaries of BRCA1 was analyzed using direct DNA sequencing. A total of 33 DNA samples from Tunisian women diagnosed with TNBC and unselected for family history or age at onset were analyzed. RESULTS: The 5382inC mutation was identified in 2 out of 33 women with TNBC with an overall prevalence of 6% (2/33). The detection rate of the 5382inC mutation among TNBC women with family history of breast cancer was 25% (2/8). The two 5382inC mutation carriers were postmenopausal and diagnosed at the age of 50 and 57. When stratified by age, the frequency of BRCA1 mutation in patients diagnosed at age ≥ 50 years was 8.7% (2/23). CONCLUSIONS: Our results confirm a noticeable contribution of BRCA1 5382inC mutation in TNBC development in Tunisia and further indicate that screening for 5382insC mutation in the BRCA1 gene is of interest in genetic testing in our population. Additionally, our data highlight that receptor triple negativity could be an effective selection criterion for BRCA1 genetic test in our population and should therefore be considered in genetic testing guidelines in Tunisia.
format Online
Article
Text
id pubmed-6458830
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64588302019-04-22 Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia Mahfoudh, Wijden Bettaieb, Inchirah Ghedira, Randa Snoussi, Kaouther Bouzid, Nadia Klayech, Zahra Gabbouj, Sallouha Remadi, Yassmine Hassen, Elham Bouaouina, Noureddine Zakhama, Abdelfateh J Transl Med Research BACKGROUND: Triple negative breast cancer (TNBC) has been classified as a disease subgroup defined by the lack of expression of estrogen and progesterone receptors as well as the absence of the human epidermal growth factor receptor-2 (HER2) overexpression. Germline mutations in the BRCA1 gene have been associated with TNBC. Approximately 70% of breast cancers arising in BRCA1 mutation carriers and up to 23% of breast cancers in BRCA2 carriers display a triple negative phenotype. However, the contribution and the frequency of BRCA1 mutations in individuals with TNBC, not specifically selected for age at diagnosis or enriched family history of breast/ovarian cancer, have not been investigated in the Tunisian population and are to be established. The aim of the present study was to assess the contribution and the prevalence of recurrent BRCA1 germline mutation (5382inC) in Tunisian women with TNBC unselected for family history or age at onset. METHODS: For BRCA1 5382inC mutation detection, the exon 20 coding region and exon–intron boundaries of BRCA1 was analyzed using direct DNA sequencing. A total of 33 DNA samples from Tunisian women diagnosed with TNBC and unselected for family history or age at onset were analyzed. RESULTS: The 5382inC mutation was identified in 2 out of 33 women with TNBC with an overall prevalence of 6% (2/33). The detection rate of the 5382inC mutation among TNBC women with family history of breast cancer was 25% (2/8). The two 5382inC mutation carriers were postmenopausal and diagnosed at the age of 50 and 57. When stratified by age, the frequency of BRCA1 mutation in patients diagnosed at age ≥ 50 years was 8.7% (2/23). CONCLUSIONS: Our results confirm a noticeable contribution of BRCA1 5382inC mutation in TNBC development in Tunisia and further indicate that screening for 5382insC mutation in the BRCA1 gene is of interest in genetic testing in our population. Additionally, our data highlight that receptor triple negativity could be an effective selection criterion for BRCA1 genetic test in our population and should therefore be considered in genetic testing guidelines in Tunisia. BioMed Central 2019-04-11 /pmc/articles/PMC6458830/ /pubmed/30975216 http://dx.doi.org/10.1186/s12967-019-1873-8 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Mahfoudh, Wijden
Bettaieb, Inchirah
Ghedira, Randa
Snoussi, Kaouther
Bouzid, Nadia
Klayech, Zahra
Gabbouj, Sallouha
Remadi, Yassmine
Hassen, Elham
Bouaouina, Noureddine
Zakhama, Abdelfateh
Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia
title Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia
title_full Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia
title_fullStr Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia
title_full_unstemmed Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia
title_short Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia
title_sort contribution of brca1 5382insc mutation in triple negative breast cancer in tunisia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458830/
https://www.ncbi.nlm.nih.gov/pubmed/30975216
http://dx.doi.org/10.1186/s12967-019-1873-8
work_keys_str_mv AT mahfoudhwijden contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT bettaiebinchirah contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT ghediraranda contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT snoussikaouther contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT bouzidnadia contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT klayechzahra contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT gabboujsallouha contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT remadiyassmine contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT hassenelham contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT bouaouinanoureddine contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia
AT zakhamaabdelfateh contributionofbrca15382inscmutationintriplenegativebreastcancerintunisia